Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00155350
First received: September 8, 2005
Last updated: February 24, 2006
Last verified: August 2005

September 8, 2005
February 24, 2006
November 2004
Not Provided
changes from baseline in total plaque volume, plaque characteristics (as determined by computed tomography [CT]-density values and other morphological features), and total coronary calcium score
changes from baseline in total plaque volume, plaque characteristics (as determined by CT-density values and other morphological features), and total coronary calcium score
Complete list of historical versions of study NCT00155350 on ClinicalTrials.gov Archive Site
  • percent change from baseline in calcium volume score in each coronary artery
  • percent change from baseline in plasma glucose/insulin homeostatic parameters and various risk markers
  • and the occurrence of a composite of major cardiovascular events
percent change from baseline in calcium volume score in each coronary artery, percent change from baseline in plasma glucose/insulin homeostatic parameters and various risk markers, and the occurrence of a composite of major cardiovascular events
Not Provided
Not Provided
 
Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
Treatment of Coronary Atherosclerosis and Calcification by Insulin Sensitizers in Insulin-Resistant Patients: Evaluated by EBCT, 16-Slice MDCT Coronary Angiography/Scanning, and Intravascular Ultrasound

In this study, we, the investigators at National Taiwan University Hospital, will evaluate the efficacy of pharmacological therapy targeted to reduce insulin resistance (pioglitazone) on the progression and compositional change of non-obstructive coronary atherosclerotic plaques and coronary calcification by serial intravascular ultrasound (IVUS)/multi-detector-row computed tomography (MDCT) follow-up in patients with type 2 diabetes or non-diabetic metabolic syndrome during a 2-year period.

Background: Type 2 diabetes and its antecedent, metabolic syndrome, are important risk factors for premature and accelerated atherosclerotic cardiovascular diseases. However, glycemic control by provision of endogenous or exogenous insulin induced only modest and not statistically significant reduction of the risk of myocardial infarction. We and other investigators have demonstrated that the use of insulin sensitizer, thiazolidinediones, resulted in favorable antiatherosclerotic effects in patients with type 2 diabetes or non-diabetic metabolic syndrome. It has become increasingly clear that morbidity and mortality associated with coronary artery disease (CAD) are often associated with lesions that are not obstructive but prone to rupture, the so-called vulnerable plaques. Conventional coronary angiography is not suitable for identifying vulnerable plaques. They may be detected by intravascular ultrasound (IVUS) and recently developed high-resolution 16-slice multi-detector computed tomography (MDCT). Nevertheless, whether this modality could be used as a guide for optimizing medical treatment of CAD has never been explored in the medical literature. In this study, we will evaluate the efficacy of pharmacological therapy targeted to reduce insulin resistance on the progression and compositional change of non-obstructive coronary atherosclerotic plaques and coronary calcification by serial IVUS/MDCT follow-up in patients with type 2 diabetes or non-diabetic metabolic syndrome during a 2-year period.

Methods and Expected Results: Patients aged ≥18 years conformed to the diagnosis of type 2 diabetes or metabolic syndrome criteria in ATP III and with objective evidence of myocardial ischemia will undergo EBCT, MDCT coronary angiography, percutaneous coronary angiography and intervention if appropriate, and IVUS study if non-obstructive coronary plaques are identified in the MDCT examination. Patients deemed eligible (with one or more ≥ 20% and < 70% stenosis in at least one coronary artery) will then be randomly assigned in a 1:1 ratio to receive pioglitazone (30 mg/d) or placebo in an open-label fashion. Patients with type 2 diabetes assigned to the placebo group are not allowed to be treated with any insulin sensitizer. The target for glycemic control in patients with type 2 diabetes in both groups is reduction of HbA1c to ≤ 7.0%. A total of 120 patients are planned to be included, and the follow-up period is 2 years. To assess the progression of coronary atherosclerosis, MDCT coronary angiography/scanning will be performed at baseline and 3, 6, 12, and 24 months of follow-up. Follow-up coronary angiography and intravascular ultrasound study will be performed at 6 months if patients agree. Blood samples will also be obtained at baseline and 3, 6, 12, and 24 months of follow-up for the measurement of various conventional and novel coronary risk factors. We also obtain DNA specimen from blood drawn at baseline for genotyping. The primary end-points include changes from baseline in total plaque volume, plaque characteristics (as determined by CT-density values and other morphological features), and total coronary calcium score. The secondary end-points include percent change from baseline in calcium volume score in each coronary artery, percent change from baseline in plasma glucose/insulin homeostatic parameters and various risk markers, and the occurrence of a composite of major cardiovascular events (death from any cause, non-fatal myocardial infarction, stroke, and target vessel revascularization).

Clinical Significance: This is the first human study to assess the antiatherosclerotic effects of insulin sensitizer by directly visualizing the atherosclerotic plaques of the whole coronary trees. It will provide us great insights regarding the evolution of coronary plaques and techniques of measuring the total vulnerability burden of the coronary arteries.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
  • Coronary Atherosclerosis
  • Inflammation
  • Coronary Heart Disease
Drug: pioglitazone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
December 2007
Not Provided

Inclusion Criteria:

  • Age ≥ 18 years and the presence of type 2 diabetes mellitus or metabolic syndrome, not currently treated by thiazolidinediones. Diagnosis of metabolic syndrome is determined by criteria defined by the National Cholesterol Education Program Adult Treatment Panel III, modified to use World Health Organization (WHO) proposed waist circumference cut-points for Asians. Therefore, this requires subjects to have three or more of the following criteria:

    • waist circumference of > 90 cm in men and > 80 cm in women;
    • serum triglycerides of >= 150 mg/dl;
    • high-density lipoprotein-cholesterol (HDL-C) levels of < 40 mg/dl in men and < 50 mg/dl in women;
    • impaired fasting glucose of 110 to 125 mg/dl; or
    • blood pressure of >= 130/85 mmHg or treated hypertension.
  • Patients with objective documentation of myocardial ischemia undergoing percutaneous coronary angiography and the coronary arteriogram showing one or more ≥ 20% and < 70% stenosis, which will be left untreated at physician’s discretion, in at least one coronary artery
  • The baseline MDCT coronary angiogram revealing one or more discernible plaque(s) untreated by stenting in at least one coronary artery
  • Ability to perform all tasks related to glycemic control and risk factor management
  • Written informed consent signed

Exclusion Criteria:

  • Class III or IV heart failure
  • Creatinine > 2.0 mg/dl
  • Hepatic disease (ALT > 3 times the upper limit of normal)
  • Poorly controlled diabetes mellitus (hemoglobin A1c [HbA1c] > 13%)
  • Fasting triglycerides > 1000 mg/dl in the presence of moderate glycemic control (HbA1c < 9.0%)
  • Non-cardiac illness expected to limit survival to less than two years
  • Current alcohol or drug abuse
  • Chronic steroid use judged to interfere with the control of diabetes, exceeding 10 mg
  • Unable to understand or cooperate with protocol requirements
Both
18 Years and older
No
Contact: Tzung-Dau Wang, MD, PhD 886-2-2312-3456 ext 5632 tdwang@ha.mc.ntu.edu.tw
Taiwan
 
NCT00155350
9361701129, NSC94-2314-B-002-292
Not Provided
Not Provided
National Taiwan University Hospital
Not Provided
Principal Investigator: Tzung-Dau Wang, MD, PhD National Taiwan University Hospital
National Taiwan University Hospital
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP